Financial Daily from THE HINDU group of publications Saturday, Nov 27, 2004 |
|
|
|
|
|
Corporate
-
Announcements Marketing - New Products & Services Agri-Biz & Commodities - Animals & Livestock Indian Immunologicals launches Nimesulide injection for animals Our Bureau
Hyderabad , Nov. 26 INDIAN Immunologicals Ltd (IIL), the wholly owned subsidiary of the National Dairy Development Board (NDDB), announced the launch of the world's first Nimesulide injection for animals on Friday. Speaking to newspersons, Dr T. Sreevardhana, General Manager (Exports and Animal Health), said that the product, branded `Nimovet', has been launched after successful in-house research and clinical trials in leading veterinary colleges in the country. The product is available in 1 ml and 15 ml vials. "Nimovet's action is multifaceted and it has been proven to be a safe, fast acting and powerful non-steroidal anti-inflammatory drug (NSAID). It does not cause hyperacidity and gastritis associated with other conventional NSAIDs." Dr Sreevardhana said that the traditional NSAID therapy in India, though effective as analgesic and anti-inflammatory, has been associated with severe side effects such as hyperacidity, gastric irritation and toxicity. "While these limitations were taken up seriously in human health to warrant further research in the quest for safer drugs, the older, harmful drugs continue to be used in veterinary NSAID therapy. These traditional NSAIDs cause undesirable side effects to animals and pose threat to our ecosystems." According to him, while Nimesulide is available in oral form in human medicare, the company has developed the molecule as an injectible for the first time in the country for veterinary healthcare. IIL expects to garner a market share of around five per cent in the domestic veterinary pain management drugs market, estimated at around Rs 27 crore, in the first year itself.
More Stories on : Announcements | New Products & Services | Animals & Livestock | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|